Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bibby

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Cancer Research|July 29, 2010
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinasesJennifer M Atkinson, Robert A Falconer, Dylan R Edwards, et al.
Molecular Cancer Therapeutics|June 19, 2003
Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug developmentPaul Gibson, Jason H Gill, Parveen A Khan, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 31, 2018
ERS/EACTS statement on the management of malignant pleural effusionsAnna C Bibby, Patrick Dorn, Ioannis Psallidas, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsH R Hendriks, P E Pizao, D P Berger, et al.
Molecular Cancer Therapeutics|December 7, 2002
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazolesTracey D Bradshaw, Michael C Bibby, John A Double, et al.
Chest|November 28, 2014
Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK CentersAnna C Bibby, Amelia O Clive, Gerry C Slade, et al.
The European Respiratory Journal|July 29, 2018
ERS/EACTS statement on the management of malignant pleural effusionsAnna C Bibby, Patrick Dorn, Ioannis Psallidas, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2013
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaAnna K Nowak, Chris Brown, Michael J Millward, et al.
Science (New York, N.Y.)|February 24, 2001
Databases tailored for biodiversity conservationA T Smith, L Boitani, C Bibby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta Pal, Arun Azad, Shailender Bhatia, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Cancer Research|July 29, 2010
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinasesJennifer M Atkinson, Robert A Falconer, Dylan R Edwards, et al.
Molecular Cancer Therapeutics|June 19, 2003
Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug developmentPaul Gibson, Jason H Gill, Parveen A Khan, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 31, 2018
ERS/EACTS statement on the management of malignant pleural effusionsAnna C Bibby, Patrick Dorn, Ioannis Psallidas, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsH R Hendriks, P E Pizao, D P Berger, et al.
Molecular Cancer Therapeutics|December 7, 2002
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazolesTracey D Bradshaw, Michael C Bibby, John A Double, et al.
Chest|November 28, 2014
Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK CentersAnna C Bibby, Amelia O Clive, Gerry C Slade, et al.
The European Respiratory Journal|July 29, 2018
ERS/EACTS statement on the management of malignant pleural effusionsAnna C Bibby, Patrick Dorn, Ioannis Psallidas, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2013
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaAnna K Nowak, Chris Brown, Michael J Millward, et al.
Science (New York, N.Y.)|February 24, 2001
Databases tailored for biodiversity conservationA T Smith, L Boitani, C Bibby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta Pal, Arun Azad, Shailender Bhatia, et al.
Pageof 21